Useless crap. They don't even bother to tell us how many got fully recovered. And using the subjective Rankin scale for measuring anything is stroke in worthless. Comparing failures and suggesting those outcomes are ok is not the way research should be done.
The latest here:
A Subanalysis From the DEFUSE 3 Trial
Educational Objective
To determine whether patients with
ischemic stroke with large-vessel occlusion in the anterior circulation
who were transferred from outside facilities for endovascular
thrombectomy have similar outcomes(So the comparison is to failure to fully recover?) in the late window compared with
patients who were directly admitted to thrombectomy-capable hospitals.
1 Credit
CME
JAMA Neurology
June 1, 2019
Original Investigation
Question
Do patients with ischemic stroke with large-vessel occlusion
in the anterior circulation who were transferred from outside facilities
and had penumbral imaging mismatch prior to endovascular thrombectomy
have similar outcomes with thrombectomy in the late window as those who
were directly admitted to thrombectomy-capable hospitals?
Findings
In this secondary analysis of a randomized clinical trial,
transfer and direct patients had comparable rates of functional
independence(How many got 100% recovered? THAT IS THE CORRECT ENDPOINT. Not the tyranny of low expectations you want us to accept.) and similar treatment effect with endovascular thrombectomy
as well as similar symptomatic intracranial hemorrhage and mortality.
Meaning
Transferring patients for late-window thrombectomy may be
associated with substantial clinical benefits and should be encouraged.
Importance
Although thrombectomy benefit was maintained in transfer
patients with ischemic stroke in early-window trials, overall functional
independence rates were lower in thrombectomy and medical
management–only groups.
Objective
To evaluate whether the imaging-based selection criteria used
in the Endovascular Therapy Following Imaging Evaluation for Ischemic
Stroke 3 (DEFUSE 3) trial would lead to comparable outcome rates and
treatment benefits in transfer vs direct-admission patients.
Design, Setting, and Participants
Subgroup analysis of DEFUSE 3, a prospective, randomized,
multicenter, blinded–end point trial. Patients were enrolled between May
2016 and May 2017 and were followed up for 90 days. The trial comprised
38 stroke centers in the United States and 182 patients with stroke
with a large-vessel anterior circulation occlusion and initial infarct
volume of less than 70 mL, mismatch ratio of at least 1.8, and mismatch
volume of at least 15 mL, treated within 6 to 16 hours from last known
well. Patients were stratified based on whether they presented directly
to the study site or were transferred from a primary center. Data were
analyzed between July 2018 and October 2018.
Interventions or Exposures
Endovascular thrombectomy plus standard medical therapy vs standard medical therapy alone.
Main Outcomes and Measures
The primary outcome was the distribution of 90-day modified Rankin Scale scores.
Results
Of the 296 patients who consented, 182 patients were
randomized (66% were transfer patients and 34% directly presented to a
study site). Median age was 71 years (interquartile range [IQR], 60-79
years) vs 70 years (IQR, 59-80 years); 69 transfer patients were women
(57%) and 23 of the direct group were women (37%). Transfer patients had
longer median times from last known well to study site arrival (9.43 vs
9 hours) and more favorable collateral profiles (based on hypoperfusion
intensity ratio): median for transfer, 0.35 (IQR, 0.18-0.47) vs 0.42
(IQR, 0.25-0.56) for direct (P = .05). The primary outcome
(90-day modified Rankin Scale score shift) did not differ in the direct
vs transfer groups (direct OR, 2.9; 95% CI, 1.2-7.2; P = .01; transfer OR, 2.6; 95% CI, 1.3-4.8; P = .009).
The overall functional independence rate (90-day modified Rankin Scale
score 0-2) in the thrombectomy group did not differ (direct 44% vs
transfer 45%) nor did the treatment effect (direct OR, 2.0; 95% CI,
0.9-4.4 vs transfer OR, 3.1; 95% CI, 1.6-6.1). Thrombectomy reperfusion
rates, mortality, and symptomatic intracranial hemorrhage rates did not
differ.
Conclusions and Relevance
In late-window patients selected by penumbral mismatch
criteria, both the favorable outcome rate and treatment effect did not
decline in transfer patients. These results have health care
implications indicating transferring potential candidates for
late-window thrombectomy is associated with substantial clinical
benefits and should be encouraged.
Trial Registration
ClinicalTrials.gov identifier: NCT02586415
No comments:
Post a Comment